NRx Pharmaceuticals, Inc. (NRXP)
USD 1.55
(-5.79%)
USD 1.55
(-5.79%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -21.65 Million | -39.75 Million | -37.7 Million | -2.26 Million | -792.73 Thousand | -473.18 Thousand |
| Net Income | -30.15 Million | -39.75 Million | -93.06 Million | -51.77 Million | 408.42 Thousand | 66.1 Thousand |
| Depreciation & Amortization | 5000.00 | 4000.00 | 2000.00 | 2000.00 | 0.86 | - |
| Deferred income taxes | -2.65 Million | - | -1.81 Million | 5.71 Million | 70.4 Thousand | - |
| Stock-based compensation | 387 Thousand | 3.62 Million | 7.78 Million | 730 Thousand | 933.90 | - |
| Change in working capital | 5.16 Million | 699 Thousand | -4.89 Million | 3.45 Million | 4662.00 | 549.62 Thousand |
| Other non-cash items | 5.59 Million | -4.33 Million | 54.28 Million | 39.61 Million | -1.27 Million | -1.55 Million |
| Investing Cash Flow | -3000.00 | -10 Thousand | -7000.00 | -2000.00 | 40.24 Million | -647.6 Thousand |
| Investments in PPE | -3000.00 | -10 Thousand | -7000.00 | -2000.00 | -3.55 | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | -3000.00 | -10 Thousand | -7000.00 | - | -993.09 Thousand | -690 Thousand |
| Sales/Maturities of investments | - | - | - | - | 41.23 Million | 42.39 Thousand |
| Other Investing Activities | 3000.00 | 10 Thousand | 7000.00 | 26.17 Million | 3.55 | -647.6 Thousand |
| Financing Cash Flow | 6.2 Million | 32.21 Million | 63.45 Million | 3.24 Million | -39.46 Million | 682.5 Thousand |
| Debt repayment | -3.09 Million | -518 Thousand | -1.27 Million | -620 Thousand | -1.26 Million | -690 Thousand |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | -40.72 Million | - |
| Common Stock Issuance | 9.29 Million | 22.7 Million | 36.98 Million | 2.57 Million | - | -7500.00 |
| Other Financing Activities | 5.03 Million | 10.03 Million | 27.74 Million | 1.29 Million | 5802.00 | 682.5 Thousand |
| Accounts receivables | - | - | 831 Thousand | -831 Thousand | - | - |
| Accounts payables | 2.65 Million | -1.61 Million | -19 Thousand | 1.18 Million | 71.34 Thousand | 465.42 Thousand |
| Inventory | - | - | - | - | - | - |
| Other working capital | 2.5 Million | 2.31 Million | -5.71 Million | 3.1 Million | -66.68 Thousand | 84.19 Thousand |
| Cash at beginning of period | 20.05 Million | 27.6 Million | 1.85 Million | 877 Thousand | 11.07 Thousand | 449.37 Thousand |
| Cash at end of period | 4.59 Million | 20.05 Million | 27.6 Million | 1.85 Million | 6.00 | 11.07 Thousand |
| Capital Expenditure | -3000.00 | -10 Thousand | -7000.00 | -2000.00 | -3.55 | - |
| Effect of forex changes on cash | - | - | - | - | 11.95 Thousand | - |
| Net cash flow / Change in cash | -15.45 Million | -7.55 Million | 25.74 Million | 982 Thousand | -11.07 Thousand | -438.29 Thousand |
| Free Cash Flow | -21.66 Million | -39.76 Million | -37.71 Million | -2.26 Million | -792.73 Thousand | -473.18 Thousand |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -7.89 Million | -6.52 Million | -4.33 Million | -30.15 Million | -6.06 Million | -8.71 Million |
| Depreciation & Amortization | 1000.00 | 1000.00 | 1000.00 | 5000.00 | 2000.00 | 1000.00 |
| Deferred income taxes | - | - | 2.2 Million | -2.65 Million | -26 Thousand | 11 Thousand |
| Stock-based compensation | 97 Thousand | 242 Thousand | -1.2 Million | 387 Thousand | 351 Thousand | 544 Thousand |
| Change in working capital | 2.1 Million | 2.28 Million | 2.42 Million | 5.16 Million | 812 Thousand | -564 Thousand |
| Other non-cash items | 171 Thousand | -1.52 Million | -2.28 Million | 5.59 Million | 359 Thousand | 913 Thousand |
| Investing Cash Flow | - | - | 1000.00 | -3000.00 | -2000.00 | 2000.00 |
| Investments in PPE | - | - | 4000.00 | -3000.00 | -2000.00 | 2000.00 |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | -3000.00 | -3000.00 | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | -3000.00 | 3000.00 | - | - |
| Financing Cash Flow | 4.08 Million | 395 Thousand | -1.11 Million | 6.2 Million | -1.5 Million | 6.27 Million |
| Debt repayment | -942 Thousand | -2.15 Million | -1.11 Million | -3.09 Million | -2.67 Million | -696 Thousand |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 3.14 Million | 2.55 Million | -8.12 Million | 9.29 Million | 1.17 Million | 5.57 Million |
| Other Financing Activities | - | -1.12 Million | 10.37 Million | 5.03 Million | - | 6273.00 |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | 2.11 Million | 2.09 Million | 1 Million | 2.65 Million | 1.52 Million | -1.56 Million |
| Inventory | - | - | - | - | - | - |
| Other working capital | -14 Thousand | 196 Thousand | 1.42 Million | 2.5 Million | -713 Thousand | 1 Million |
| Cash at beginning of period | 1.31 Million | 4.59 Million | 8.9 Million | 20.05 Million | 14.96 Million | 16.5 Million |
| Cash at end of period | 1.89 Million | 1.31 Million | 4.59 Million | 4.59 Million | 8.9 Million | 14.96 Million |
| Capital Expenditure | - | - | 4000.00 | -3000.00 | -2000.00 | 2000.00 |
| Effect of forex changes on cash | - | - | 7.18 Million | - | - | -7.18 Million |
| Net cash flow / Change in cash | 579 Thousand | -3.27 Million | -4.3 Million | -15.45 Million | -6.06 Million | -1.53 Million |
| Free Cash Flow | -3.5 Million | -3.67 Million | -3.18 Million | -21.66 Million | -4.56 Million | -7.81 Million |
0HYJ
NWBI
1949
MTC
TSGTF
002690